Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.

Panchal RG, Bradfute SB, Peyser BD, Warfield KL, Ruthel G, Lane D, Kenny TA, Anderson AO, Raschke WC, Bavari S.

Cell Host Microbe. 2009 Aug 20;6(2):162-73. doi: 10.1016/j.chom.2009.07.003.

2.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

3.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

4.

Persistent infection with ebola virus under conditions of partial immunity.

Gupta M, Mahanty S, Greer P, Towner JS, Shieh WJ, Zaki SR, Ahmed R, Rollin PE.

J Virol. 2004 Jan;78(2):958-67.

5.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

6.

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7.

PMID:
17940980
7.

Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.

Mahanty S, Gupta M, Paragas J, Bray M, Ahmed R, Rollin PE.

Virology. 2003 Aug 1;312(2):415-24.

8.

Targeting CD45RB alters T cell migration and delays viral clearance.

Lim B, Sutherland RM, Zhan Y, Deliyannis G, Brown LE, Lew AM.

Int Immunol. 2006 Feb;18(2):291-300. Epub 2005 Dec 16.

PMID:
16361310
9.

CD45 regulates apoptosis in peripheral T lymphocytes.

Liu Z, Dawes R, Petrova S, Beverley PC, Tchilian EZ.

Int Immunol. 2006 Jun;18(6):959-66. Epub 2006 Apr 18.

PMID:
16621865
10.

Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice.

Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S413-20.

PMID:
17940978
11.

Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.

Marzi A, Wegele A, Pöhlmann S.

Virology. 2006 Sep 1;352(2):345-56. Epub 2006 Jun 13.

12.

Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.

Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB.

Virology. 2002 Feb 1;293(1):15-9.

13.

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I.

J Infect Dis. 2006 Jun 15;193(12):1650-7. Epub 2006 May 10.

PMID:
16703508
14.

Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.

Geisbert TW, Hensley LE.

Expert Rev Mol Med. 2004 Sep 21;6(20):1-24. Review.

PMID:
15383160
15.

Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.

Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, Tetsutani K, Ishida H, Himeno K, Hisaeda H.

Vaccine. 2009 Oct 19;27(44):6154-9. doi: 10.1016/j.vaccine.2009.08.026. Epub 2009 Aug 25.

PMID:
19712768
16.

Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.

Hill-Batorski L, Halfmann P, Marzi A, Lopes TJ, Neumann G, Feldmann H, Kawaoka Y.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S329-35. doi: 10.1093/infdis/jiv335. Epub 2015 Jul 23.

17.

Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice.

Zumbrun EE, Abdeltawab NF, Bloomfield HA, Chance TB, Nichols DK, Harrison PE, Kotb M, Nalca A.

Viruses. 2012 Dec 3;4(12):3468-93. doi: 10.3390/v4123468. Review.

18.

Disease associations and altered immune function in CD45 138G variant carriers.

Boxall S, Stanton T, Hirai K, Ward V, Yasui T, Tahara H, Tamori A, Nishiguchi S, Shiomi S, Ishiko O, Inaba M, Nishizawa Y, Dawes R, Bodmer W, Beverley PC, Tchilian EZ.

Hum Mol Genet. 2004 Oct 15;13(20):2377-84. Epub 2004 Aug 27.

PMID:
15333587
19.

Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents.

Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S421-9.

PMID:
17940979
20.

Involvement of vacuolar protein sorting pathway in Ebola virus release independent of TSG101 interaction.

Silvestri LS, Ruthel G, Kallstrom G, Warfield KL, Swenson DL, Nelle T, Iversen PL, Bavari S, Aman MJ.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S264-70.

PMID:
17940959

Supplemental Content

Support Center